Literature DB >> 2456702

Normal histology of the prostate.

J E McNeal1.   

Abstract

The prostate gland contains three major glandular regions--the peripheral zone, the central zone, and the transition zone--which differ histologically and biologically. The central zone is relatively resistant to carcinoma and other disease; the transition zone is the main site of origin of prostate hyperplasia. There are also several important nonglandular regions concentrated in the anteromedial portion of the gland. Each glandular zone has specific architectural and stromal features. In all zones, both ducts and acini are lined by secretory epithelium. In each zone, there is a layer of basal cells beneath the secretory lining, as well as interspersed endocrine-paracrine cells. Frequent deviations from normal histology include post-inflammatory atrophy, basal cell hyperplasia, benign nodular hyperplasia, atypical adenomatous hyperplasia, and duct-acinar dysplasia. These lesions may at times be confused with carcinoma, especially in biopsy material.

Entities:  

Mesh:

Year:  1988        PMID: 2456702     DOI: 10.1097/00000478-198808000-00003

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  105 in total

1.  Voltage-dependent ion channel currents in putative neuroendocrine cells dissociated from the ventral prostate of rat.

Authors:  Jun Hee Kim; Sun Young Shin; Sang Soon Yun; Tae Jin Kim; Seung-June Oh; Kwang Myung Kim; Young-Shin Chung; Eun-Kyoung Hong; Dae-Yong Uhm; Sung Joon Kim
Journal:  Pflugers Arch       Date:  2003-02-21       Impact factor: 3.657

2.  Normal anatomic relationship between urethral sphincter complex and zones of prostrate in young Chinese males on MRI.

Authors:  Xiangdong Wang; Tieyan Liu; Jing Zhao; Jingyi Sun; Yuefeng Chen; Pengyu Sun; Xuesong Wang; Sheng Liu
Journal:  Int J Clin Exp Med       Date:  2015-09-15

3.  Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis.

Authors:  A M De Marzo; V L Marchi; J I Epstein; W G Nelson
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

4.  Molecular differences in transition zone and peripheral zone prostate tumors.

Authors:  Jennifer A Sinnott; Jennifer R Rider; Jessica Carlsson; Travis Gerke; Svitlana Tyekucheva; Kathryn L Penney; Howard D Sesso; Massimo Loda; Katja Fall; Meir J Stampfer; Lorelei A Mucci; Yudi Pawitan; Sven-Olof Andersson; Ove Andrén
Journal:  Carcinogenesis       Date:  2015-04-13       Impact factor: 4.944

Review 5.  Benign prostatic hyperplasia and its treatment.

Authors:  J B Stimson; S D Fihn
Journal:  J Gen Intern Med       Date:  1990 Mar-Apr       Impact factor: 5.128

Review 6.  Basic principles of anatomy for optimal surgical treatment of prostate cancer.

Authors:  Jochen Walz; Markus Graefen; Hartwig Huland
Journal:  World J Urol       Date:  2007-02-27       Impact factor: 4.226

7.  Two-dimensional MR spectroscopy of healthy and cancerous prostates in vivo.

Authors:  M Albert Thomas; Thomas Lange; S Sendhil Velan; Rajakumar Nagarajan; Steve Raman; Ana Gomez; Daniel Margolis; Stephany Swart; Raymond R Raylman; Rolf F Schulte; Peter Boesiger
Journal:  MAGMA       Date:  2008-07-17       Impact factor: 2.310

8.  Prostatic intra-epithelial neoplasia: expression and location of proliferating cell nuclear antigen in epithelial, endothelial and stromal nuclei.

Authors:  R Montironi; C M Galluzzi; L Diamanti; I Giannulis; E Pisani; M Scarpelli
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

Review 9.  The significance of atypical adenomatous hyperplasia and prostatic intraepithelial neoplasia for the development of prostate carcinoma. An update.

Authors:  B G Helpap; D G Bostwick; R Montironi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

10.  Nonhuman primates as models for studies of prostate specific antigen and prostatic diseases.

Authors:  James N Mubiru; Gene B Hubbard; Edward J Dick; Jaime Furman; Dean A Troyer; Jeffrey Rogers
Journal:  Prostate       Date:  2008-10-01       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.